40 related articles for article (PubMed ID: 9231304)
1. Clozapine versus typical neuroleptic medication for schizophrenia.
Essali A; Al-Haj Haasan N; Li C; Rathbone J
Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD000059. PubMed ID: 19160174
[TBL] [Abstract][Full Text] [Related]
2. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
[TBL] [Abstract][Full Text] [Related]
3. Predictors and markers of clozapine response.
Chung C; Remington G
Psychopharmacology (Berl); 2005 May; 179(2):317-35. PubMed ID: 15717209
[TBL] [Abstract][Full Text] [Related]
4. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P; Ratner S; Laor N; Weizman A
Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
[TBL] [Abstract][Full Text] [Related]
5. Tolerability profile of atypical antipsychotics in children and adolescents.
Stigler KA; Potenza MN; McDougle CJ
Paediatr Drugs; 2001; 3(12):927-42. PubMed ID: 11772153
[TBL] [Abstract][Full Text] [Related]
6. Atypical neuroleptics in child and adolescent psychiatry.
Remschmidt H; Hennighausen K; Clement HW; Heiser P; Schulz E
Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I9-19. PubMed ID: 11140784
[TBL] [Abstract][Full Text] [Related]
7. Management of schizophrenia in children and adolescents. The role of clozapine.
Remschmidt H; Fleischhaker C; Hennighausen K; Schulz E
Paediatr Drugs; 2000; 2(4):253-62. PubMed ID: 10946414
[TBL] [Abstract][Full Text] [Related]
8. [Clozapine and treatment of negative symptoms].
Lançon C; Farisse J; Llorca PM
Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
[TBL] [Abstract][Full Text] [Related]
9. Clozapine response and plasma catecholamines and their metabolites.
Green AI; Alam MY; Sobieraj JT; Pappalardo KM; Waternaux C; Salzman C; Schatzberg AF; Schildkraut JJ
Psychiatry Res; 1993 Feb; 46(2):139-49. PubMed ID: 8483973
[TBL] [Abstract][Full Text] [Related]
10. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia.
Schulz E; Fleischhaker C; Remschmidt HE
J Child Adolesc Psychopharmacol; 1996; 6(2):119-31. PubMed ID: 9231304
[TBL] [Abstract][Full Text] [Related]
11. Blood biogenic amines during clozapine treatment of early-onset schizophrenia.
Schulz E; Fleischhaker C; Clement HW; Remschmidt H
J Neural Transm (Vienna); 1997; 104(10):1077-89. PubMed ID: 9503259
[TBL] [Abstract][Full Text] [Related]
12. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia.
Fleischhaker C; Schulz E; Remschmidt H
J Psychiatr Res; 1998; 32(5):325-33. PubMed ID: 9789212
[TBL] [Abstract][Full Text] [Related]
13. [Effect of clozapine on biogenic amines within the scope of drug treatment of schizophrenic psychoses in adolescence].
Schulz E; Remschmidt H; Fleischhaker C
Z Kinder Jugendpsychiatr; 1994 Dec; 22(4):285-98. PubMed ID: 7856324
[TBL] [Abstract][Full Text] [Related]
14. [Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence].
Fleischhaker C; Schulz E; Remschmidt H
Z Kinder Jugendpsychiatr Psychother; 1998 Dec; 26(4):235-43. PubMed ID: 9880833
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
